CA2870252A1 - Method for treating irritable bowel syndrome with diarrhea - Google Patents

Method for treating irritable bowel syndrome with diarrhea Download PDF

Info

Publication number
CA2870252A1
CA2870252A1 CA2870252A CA2870252A CA2870252A1 CA 2870252 A1 CA2870252 A1 CA 2870252A1 CA 2870252 A CA2870252 A CA 2870252A CA 2870252 A CA2870252 A CA 2870252A CA 2870252 A1 CA2870252 A1 CA 2870252A1
Authority
CA
Canada
Prior art keywords
hydroxy
alkyl
fatty acid
bowel syndrome
irritable bowel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2870252A
Other languages
English (en)
French (fr)
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of CA2870252A1 publication Critical patent/CA2870252A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2870252A 2012-04-23 2013-04-19 Method for treating irritable bowel syndrome with diarrhea Abandoned CA2870252A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261637082P 2012-04-23 2012-04-23
US61/637,082 2012-04-23
US201261718924P 2012-10-26 2012-10-26
US61/718,924 2012-10-26
PCT/JP2013/062309 WO2013161973A1 (en) 2012-04-23 2013-04-19 Method for treating irritable bowel syndrome with diarrhea

Publications (1)

Publication Number Publication Date
CA2870252A1 true CA2870252A1 (en) 2013-10-31

Family

ID=49380683

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2870252A Abandoned CA2870252A1 (en) 2012-04-23 2013-04-19 Method for treating irritable bowel syndrome with diarrhea

Country Status (7)

Country Link
US (1) US20130281526A1 (enExample)
EP (1) EP2841065A4 (enExample)
JP (1) JP2015514681A (enExample)
CN (2) CN108685929A (enExample)
CA (1) CA2870252A1 (enExample)
TW (1) TWI594751B (enExample)
WO (1) WO2013161973A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203317A1 (en) * 2015-06-19 2016-12-22 Sucampo Ag Pharmaceutical compositions comprising fatty acid derivative

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05006981A (es) * 2002-12-27 2005-12-14 Sucampo Ag Derivados de prostaglandinas para el tratamiento de la molestia abdominal.
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2009045985A1 (en) * 2007-10-01 2009-04-09 The University Of Chicago Treatment of drug-induced nausea with opioid antagonists
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
WO2009131200A1 (ja) * 2008-04-25 2009-10-29 協和発酵キリン株式会社 過敏性腸症候群治療剤
CN103919804A (zh) * 2008-05-01 2014-07-16 利发利希奥公司 治疗消化功能紊乱的组合物和方法
JPWO2010016552A1 (ja) * 2008-08-07 2012-01-26 武田薬品工業株式会社 過敏性腸症候群治療薬
EP2778685B1 (en) * 2009-06-25 2017-04-26 Nestec S.A. Methods for diagnosing irritable bowel syndrome
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali

Also Published As

Publication number Publication date
CN108685929A (zh) 2018-10-23
CN104379140A (zh) 2015-02-25
TWI594751B (zh) 2017-08-11
US20130281526A1 (en) 2013-10-24
TW201347757A (zh) 2013-12-01
EP2841065A1 (en) 2015-03-04
JP2015514681A (ja) 2015-05-21
WO2013161973A1 (en) 2013-10-31
EP2841065A4 (en) 2015-09-16

Similar Documents

Publication Publication Date Title
US6982283B2 (en) Method for treating drug-induced constipation
CA2510051C (en) Derivatives of prostaglandins for treating abdominal discomfort
CA2502439C (en) Prostaglandin compounds for the treatment of obesity
WO2015050277A1 (en) Selective tumor treatment
AU2010237744A1 (en) Method and composition for treating macular degeneration
CA2691102C (en) Pharmaceutical combination of opioid and prostaglandin compound
CA2577284A1 (en) Prostaglandin derivatives for treating gastrointestinal disorder
JP6193230B2 (ja) 統合失調症の処置方法
CA2870252A1 (en) Method for treating irritable bowel syndrome with diarrhea
US20080207759A1 (en) Method for protecting mitochondria
US20100305203A1 (en) Method for modulating claudin mediated functions
WO2015025980A1 (en) Method for treating neuropathic pain
US8569279B2 (en) Method for modulating claudin mediated functions
WO2016067620A1 (en) Method and composition for treating nonerosive reflux disease
US20120277299A1 (en) Method for modulating ion transporter

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190423